did some dd on $CBIS - Cannabis Science, Inc>>>
Post# of 88914
Posted On: 07/16/2015 11:28:39 PM
did some dd on $CBIS - Cannabis Science, Inc>>>
CBIS Business Overview>>>
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate.
The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
CBIS Website>> http://www.cannabisscience.com/
CBIS Products & Services>>
Cannabis Science alleviates suffering and promotes health through cannabinoid science. A pioneering biotech company, Cannabis Science creates cannabinoid-based extract formulations for various medical conditions, including more than 8 different types of Cancer.
Our products, broadly described, are medical cannabinoid products developed from one or more of the cannabinoid compounds found in the cannabis plant.
Cannabis sativa is one of the most widely used plants for both recreational and medicinal purposes. To date a total of 525 natural constituents covering several chemical classes have been isolated and identified from Cannabis sativa. The cannabinoids belong to the chemical class of terpenophenolics, of which 85 have been uniquely identified in cannabis, including the most psychoactive cannabinoid, tetrahydrocannabinol commonly referred to as THC.
The most common natural plant cannabinoids (phytocannabinoids) are: THC, cannabidiol (CBD), cannabigerol (CBG), cannabichromene (CBC), and cannabinol (CBN). Several of the identified cannabinoids are both chemically and pharmacologically poorly characterized; however, the pharmacology of THC has been widely studied, and it is regarded as the main psychoactive constituent of cannabis.
Cannabinoids were first discovered in the 1940s, when CBD and CBN were identified. THC was not identified until 1964, but by that time cannabinoids had been removed from the pharmacopeiae of most countries, making further research on the plant difficult.
There are three general types of cannabinoids:
Phytocannabinoids, that occur uniquely in the cannabis plant.
Endogenous cannabinoids produced naturally in many animal species including humans.
Synthetic cannabinoids compounds produced in a laboratory. Forms of synthetic THC are available by prescription in a number of countries, including the US. In the US, marketed as Marinol®.
Phytocannabinoids, also called natural cannabinoids, herbal cannabinoids, and classical cannabinoids, are only known to occur naturally in significant quantity in the cannabis plant. They are concentrated in a viscous resin that is produced in glandular structures known as trichomes, and are most prevalent in the flowers of the female plants.
Cannabinoid receptors in the human body were not discovered until 1988. CB1 receptors are found throughout the body and are the most prevalent neurotransmitter system in the brain, specifically in the basal ganglia and in the limbic system, including the hippocampus. They are also found in the cerebellum and in both male and female reproductive systems.
CB2 receptors are found most exclusively in the immune system, with the greatest density in the spleen. CB2 receptors appear to be responsible for the anti-inflammatory and possibly other therapeutic effects of cannabis. CB2 receptors appear in any tissue when there is pathology.
The endocannabinoid system refers to a group of neuromodulators and receptors involved in a variety of physiological processes including appetite, pain sensation, mood, and memory. The system is named for endocannabinoids, the endogenous lipids that bind cannabinoid receptors.
Science increasingly recognizes the role that endo-cannabinoids play in major life functions in the human body. Cannabinoids act as a bio regulatory mechanism, which explains why they have been recommended as a treatment for many diseases and ailments in anecdotal reports and scientific literature. Common prescribed ailments include: Pain, arthritic conditions, migraine headaches, anxiety, epileptic seizures, insomnia, loss of appetite, GERD (chronic heartburn), nausea, glaucoma, AIDS wasting syndrome, depression, bipolar disorder (particularly depression-manic-normal), multiple sclerosis, menstrual cramps, Parkinson's, trigeminal neuralgia (tic douloureux), high blood pressure, irritable bowel syndrome, and bladder incontinence.
Cannabinoids have been used medicinally for thousands of years in China, India, and the Middle East. Of course, most traditional medicines were plant-based, but until recently no one knew how or why they worked. Though cannabinoids are a very old form of medication, we are inspired by this "folk medicine," whose efficacy modern science now routinely verifies, and we are capable of creating systematic and effective use of cannabinoid therapies.
While cannabinoids were widely used in the West during the 19th century, the technology was lacking to detect and understand its active ingredients, to standardize dosages of those ingredients, and to effectively deliver those ingredients, owing largely to cannabinoids' non-water-solubility. Consequently, it became less widely used in the early 20th century and was eventually renamed "marijuana". It was gradually removed from the pharmacopeiae of most advanced countries; and research was discouraged.
Management
Raymond C. Dabney - President & CEO, Co-Founder and Director
Mr. Raymond C. Dabney, President & CEO, brings 25 years of experience in corporate finance, corporate structure, corporate communications, sales and marketing for public companies. Mr. Dabney has significant experience in public and private venture capital, early stage equity/debt financings and regulatory compliance.
Mr. Dabney has co-founded several public and private companies in many diverse industries such as drug development, entertainment, media, advertising, mining, automobile, high-tech, manufacturing, real estate and communications, many of which he launched from day one. Cannabis Science is a prime example of the type of organizations that Mr. Dabney has built from inception. Mr. Dabney has extensive international relationships that he has utilized to grow each Company, from the US, Canada, several European centers, such as Paris, London, Amsterdam and eastern Spain, as well as countries in the West Indies, South America, and Asia. Mr. Dabney’s niche market knowledge, team leadership, and management style facilitate the continued growth and forward thinking that successfully bring his projects from concept to completion.
CBIS Stock Information>>
http://www.otcmarkets.com/stock/CBIS/filings
CBIS Headlines and Accomplishments>>>
http://finance.yahoo.com/q/h?s=CBIS+Headlines
CBIS SS>>>
http://www.otcmarkets.com/stock/CBIS/profile
CBIS Chart>>> http://stockcharts.com/h-sc/ui?s=CBIS&p=D...9870498400
CBIS Business Overview>>>
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate.
The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
CBIS Website>> http://www.cannabisscience.com/
CBIS Products & Services>>
Cannabis Science alleviates suffering and promotes health through cannabinoid science. A pioneering biotech company, Cannabis Science creates cannabinoid-based extract formulations for various medical conditions, including more than 8 different types of Cancer.
Our products, broadly described, are medical cannabinoid products developed from one or more of the cannabinoid compounds found in the cannabis plant.
Cannabis sativa is one of the most widely used plants for both recreational and medicinal purposes. To date a total of 525 natural constituents covering several chemical classes have been isolated and identified from Cannabis sativa. The cannabinoids belong to the chemical class of terpenophenolics, of which 85 have been uniquely identified in cannabis, including the most psychoactive cannabinoid, tetrahydrocannabinol commonly referred to as THC.
The most common natural plant cannabinoids (phytocannabinoids) are: THC, cannabidiol (CBD), cannabigerol (CBG), cannabichromene (CBC), and cannabinol (CBN). Several of the identified cannabinoids are both chemically and pharmacologically poorly characterized; however, the pharmacology of THC has been widely studied, and it is regarded as the main psychoactive constituent of cannabis.
Cannabinoids were first discovered in the 1940s, when CBD and CBN were identified. THC was not identified until 1964, but by that time cannabinoids had been removed from the pharmacopeiae of most countries, making further research on the plant difficult.
There are three general types of cannabinoids:
Phytocannabinoids, that occur uniquely in the cannabis plant.
Endogenous cannabinoids produced naturally in many animal species including humans.
Synthetic cannabinoids compounds produced in a laboratory. Forms of synthetic THC are available by prescription in a number of countries, including the US. In the US, marketed as Marinol®.
Phytocannabinoids, also called natural cannabinoids, herbal cannabinoids, and classical cannabinoids, are only known to occur naturally in significant quantity in the cannabis plant. They are concentrated in a viscous resin that is produced in glandular structures known as trichomes, and are most prevalent in the flowers of the female plants.
Cannabinoid receptors in the human body were not discovered until 1988. CB1 receptors are found throughout the body and are the most prevalent neurotransmitter system in the brain, specifically in the basal ganglia and in the limbic system, including the hippocampus. They are also found in the cerebellum and in both male and female reproductive systems.
CB2 receptors are found most exclusively in the immune system, with the greatest density in the spleen. CB2 receptors appear to be responsible for the anti-inflammatory and possibly other therapeutic effects of cannabis. CB2 receptors appear in any tissue when there is pathology.
The endocannabinoid system refers to a group of neuromodulators and receptors involved in a variety of physiological processes including appetite, pain sensation, mood, and memory. The system is named for endocannabinoids, the endogenous lipids that bind cannabinoid receptors.
Science increasingly recognizes the role that endo-cannabinoids play in major life functions in the human body. Cannabinoids act as a bio regulatory mechanism, which explains why they have been recommended as a treatment for many diseases and ailments in anecdotal reports and scientific literature. Common prescribed ailments include: Pain, arthritic conditions, migraine headaches, anxiety, epileptic seizures, insomnia, loss of appetite, GERD (chronic heartburn), nausea, glaucoma, AIDS wasting syndrome, depression, bipolar disorder (particularly depression-manic-normal), multiple sclerosis, menstrual cramps, Parkinson's, trigeminal neuralgia (tic douloureux), high blood pressure, irritable bowel syndrome, and bladder incontinence.
Cannabinoids have been used medicinally for thousands of years in China, India, and the Middle East. Of course, most traditional medicines were plant-based, but until recently no one knew how or why they worked. Though cannabinoids are a very old form of medication, we are inspired by this "folk medicine," whose efficacy modern science now routinely verifies, and we are capable of creating systematic and effective use of cannabinoid therapies.
While cannabinoids were widely used in the West during the 19th century, the technology was lacking to detect and understand its active ingredients, to standardize dosages of those ingredients, and to effectively deliver those ingredients, owing largely to cannabinoids' non-water-solubility. Consequently, it became less widely used in the early 20th century and was eventually renamed "marijuana". It was gradually removed from the pharmacopeiae of most advanced countries; and research was discouraged.
Management
Raymond C. Dabney - President & CEO, Co-Founder and Director
Mr. Raymond C. Dabney, President & CEO, brings 25 years of experience in corporate finance, corporate structure, corporate communications, sales and marketing for public companies. Mr. Dabney has significant experience in public and private venture capital, early stage equity/debt financings and regulatory compliance.
Mr. Dabney has co-founded several public and private companies in many diverse industries such as drug development, entertainment, media, advertising, mining, automobile, high-tech, manufacturing, real estate and communications, many of which he launched from day one. Cannabis Science is a prime example of the type of organizations that Mr. Dabney has built from inception. Mr. Dabney has extensive international relationships that he has utilized to grow each Company, from the US, Canada, several European centers, such as Paris, London, Amsterdam and eastern Spain, as well as countries in the West Indies, South America, and Asia. Mr. Dabney’s niche market knowledge, team leadership, and management style facilitate the continued growth and forward thinking that successfully bring his projects from concept to completion.
CBIS Stock Information>>
http://www.otcmarkets.com/stock/CBIS/filings
CBIS Headlines and Accomplishments>>>
http://finance.yahoo.com/q/h?s=CBIS+Headlines
CBIS SS>>>
http://www.otcmarkets.com/stock/CBIS/profile
CBIS Chart>>> http://stockcharts.com/h-sc/ui?s=CBIS&p=D...9870498400
(0)
(0)Scroll down for more posts ▼